Furthermore, after silencing iRhom 1/2 genes, an attenuation of excess TNF-α release in CD was observed, and the immunosuppressive capabilities of TGF-β signaling were restored, which ultimately reverses inflammatory tissue damage, suggesting a therapeutic option to treat inflammatory autoimmune diseases such as CD and RA [120]. The gene discussed is TNF; the disease is rheumatoid arthritis.